Biosimilars | Access & Reimbursement | US/EU5 | 2021
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra and Retacrit are available both in Europe and the United States, the level of their success may vary due to regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilar developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilar uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose among multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilar discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
- Has COVID-19 affected the use or coverage of biosimilars?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Viatris (Mylan)
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Admelog/Insulin Lispro Sanofi
- Aranesp
- Avastin
- Avsola
- Basaglar/Abasaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Hulio
- Humalog
- Humira
- Inflectra
- Kanjinti
- Lantus
- Levemir
- Mvasi
- Neulasta
- Neupogen
- Nivestim/Nivestym
- NovoLog/NovoRapid
- Nyvepria
- Ogivri
- Ontruzant
- Procrit/Epogen
- Remicade
- Remsima
- Retacrit
- Riabni
- Rituxan/MabThera
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio/Zarxio
- Ziextenzo
- Zirabev
Related Market Assessment Reports
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
